<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The present study was designed to establish the incidence of cytogenetic evolution (CE), defined as the acquisition of chromosomal defects during the course of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, in order to correlate it with the WHO classification and IPSS score, and to assess its impact on overall survival (OS) and risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> evolution (progression-free interval, PFI) by means of Cox models for time-dependent covariates </plain></SENT>
<SENT sid="1" pm="."><plain>Adjustments for known risk factors were achieved by performing a bivariable analysis </plain></SENT>
<SENT sid="2" pm="."><plain>The study was carried out in 153 MDS patients who were followed for a median period of 45.2 months </plain></SENT>
<SENT sid="3" pm="."><plain>Disease progression occurred in 42.4% of patients after a 65.2-month median PFI, while CE occurred in 30.7% of patients </plain></SENT>
<SENT sid="4" pm="."><plain>Our study shows that (1) CE was more common in advanced than in early <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> presented secondary chromosomal defects distinct from those of early <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; (2) CE significantly affected OS and PFI independently of other prognostic variables; (3) del(7)(q31q34) was the only secondary chromosomal defect which significantly affected PFI; <z:mp ids='MP_0004027'>trisomy</z:mp> 8 had only a moderate influence </plain></SENT>
</text></document>